Leerink Partnrs Has Bearish Outlook for Geron Q2 Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Leerink Partnrs decreased their Q2 2025 earnings per share estimates for Geron in a report released on Monday, April 21st. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings per share of ($0.04) for the quarter, down from their prior estimate of ($0.03). The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron's Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.17) EPS and FY2026 earnings at ($0.02) EPS.

Geron (NASDAQ:GERN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million.

Several other research firms have also commented on GERN. Needham & Company LLC restated a "buy" rating and set a $5.00 price target on shares of Geron in a research report on Wednesday, March 12th. Barclays restated an "overweight" rating and issued a $4.00 price target (down previously from $9.00) on shares of Geron in a research note on Thursday, February 27th. Scotiabank reduced their price objective on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a research report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on Geron from $8.00 to $4.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Finally, B. Riley downgraded Geron from a "buy" rating to a "neutral" rating and cut their target price for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.75.

Geron Stock Performance

Shares of NASDAQ GERN opened at $1.41 on Wednesday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The firm's 50-day moving average price is $1.71 and its two-hundred day moving average price is $2.98. The stock has a market capitalization of $898.05 million, a P/E ratio of -4.41 and a beta of 0.66. Geron has a 52-week low of $1.17 and a 52-week high of $5.34.

Hedge Funds Weigh In On Geron

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in Geron in the 4th quarter valued at $28,000. Integrated Wealth Concepts LLC acquired a new position in shares of Geron in the 4th quarter worth approximately $36,000. Sowell Financial Services LLC bought a new stake in shares of Geron during the first quarter worth $43,000. GF Fund Management CO. LTD. acquired a new stake in Geron in the 4th quarter valued at about $45,000. Finally, 111 Capital acquired a new position in Geron during the 4th quarter worth $52,000. 73.71% of the stock is currently owned by institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.